Barrett’s esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies

Table 3 Efficacy of endoscopic eradication therapy for Barrett’s esophagus with low-grade dysplasia

Ref.	Type	n	CE-IM	CE-D	NNT to prevent disease progression	Annual disease progression, treatment vs placebo (P value)
Wani et al[22]	Meta-analysis	1512	-	-	65.5 (EAC)	0.16% vs 1.7% (P = 0.99) (EAC)
Shaheen et al[42]	RCT	64	81%	90.5%	11.3 (HGD)	5% vs 14% (HGD) (P = 0.33)
Shaheen et al[91]	Retrospective	52	98%	98%	NA	NA
Bulsiewicz et al[92]	Retrospective	41	93%	100%	NA	NA
Phoa et al[45]	RCT	136	88.2%	92.6%	13.6 (EAC)	1.5% vs 8.8% at 3 yr (EAC) (P = 0.03)
Qumseya et al[100]	Meta-analysis	2746	-	-	16 (EAC)	NA
Pouw et al[101]	Retrospective	83	90%	90%	11.4 (EAC)	NA
Barret et al[46]	RCT	82	37.5%	52.5%	-	5% vs 2.4% at 3 yr: (EAC) (P = 0.52)

n: Patient number; CE-D/IM: Complete eradication of dysplasia/intestinal metaplasia; EAC: Esophageal adenocarcinoma; HGD: High grade dysplasia; NNT: Number needed to treat; NA: Not application.